Athersys Inc (ATHX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

3201 CARNEGIE AVENUE CLEVELAND, OH 44115-2634

Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic product candidates in multiple disease areas in the United States. Its product pipeline includes ATHX-105, a Phase I clinical trial product for the treatment of obesity. The company also develops orally active pharmaceutical products for the treatment of central nervous system disorders that include sleep disorders, such as narcolepsy or excessive daytime sleepiness; and other potential indications, such as attention deficit hyperactivity disorder and other cognitive disorders. In addition, Athersys, through its product co-development collaboration with Angiotech Pharmaceuticals, Inc., develops MultiStem for the treatment of damage caused by myocardial infarction and peripheral vascular disease, as well as for bone marrow transplant/oncology support, ischemic stroke, and other disease indications.

Data as of 2020-11-22
Market Cap324.227 Million Shares Outstanding197.7 Million Avg 30-day Volume1.724 Million
P/E Ratio-4.4 Dividend Yield EPS-0.37
Price/Sales709.469 Price cash flow ratio Price free cash flow ratio-5.8
Book Value0.22 Price to Tangible Book7.34 Alpha0.04
Short Interest Ratio % Short Interest to Float R-squared0.081654
BETA-1.68145 52-week High/Low4.38 / 1.13 Stddev0.247969
View SEC Filings from ATHX instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 0 0 (0.0%) 0 (0.0%)
Funds Holding: 136 136 0.0% 29 (1.91%) 29 (1.88%) 0.0%
13F shares: 55.054 Million 55.544 Million -0.88% 7.878 Million 9.298 Million -15.27%
% Ownership 27.8893 28.2258 -1.19% 3.991 4.7249 -15.53%
New Positions: 23 40 -42.5% 5 10 -50.0%
Increased Positions 41 52 -21.15% 8 11 -27.27%
Closed Positions 20 13 53.85% 5 3 66.67%
Reduced Positions 31 19 63.16% 8 6 33.33%
Total Calls 746.076 Thousand 877.497 Thousand -14.98% 114.5 Thousand 137.5 Thousand -16.73%
Total Puts 1.317 Million 770.602 Thousand 70.92% 151.3 Thousand 146.6 Thousand 3.21%
PUT/CALL Ratio 1.77 0.88 101.14% 1.32 1.07 23.36%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ATHX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ATHX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WASMAN JANE

  • Director
0 2020-11-12 2

SHAH BAIJU R.

  • Director
0 2020-11-12 2

KALIN KATHERINE BACH

  • Director
0 2020-11-12 2

VAN BOKKELEN GIL CHAIRMAN AND CEO

  • Officer
  • Director
1,707,570 2020-09-17 4

LEHMANN WILLIAM JR PRESIDENT AND COO

  • Officer
490,525 2020-09-17 4

CAMPBELL LAURA K SENIOR VICE PRES FINANCE

  • Officer
442,175 2020-09-17 5

HARRINGTON JOHN J EXEC VICE PRES AND CSO

  • Officer
  • Director
761,771 2020-09-15 4

TRAUB KENNETH H

  • Director
235,093 2020-06-22 3

RANDALL LORIN

  • Director
0 2020-06-18 1

WYSZOMIERSKI JACK L

  • Director
0 2020-06-18 1

BABISS LEE

  • Director
0 2020-06-18 1

KOLA ISMAIL

  • Director
0 2020-06-18 1

MACLEOD IVOR CHIEF FINANCIAL OFFICER

  • Officer
0 2020-01-31 2

KAGIMOTO TADAHISA

  • Director
  • 10% Owner
12,000,000 2018-06-18 0

HEALIOS K.K.

  • 10% Owner
12,000,000 2018-06-06 0

DAVIS JORDAN

  • Director
0 2017-06-07 0

DEANS ROBERT J EXECUTIVE VICE PRESIDENT

  • Officer
426,639 2015-06-24 0

MILNE GEORGE M JR

  • Director
0 2011-06-16 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP III LLC

ISALY SAMUEL D

  • 10% Owner
15,250,600 2011-04-11 0

SHEFFERY MICHAEL B

  • Director
  • 10% Owner
0 2010-06-10 0

LOOP FLOYD D MD

  • Director
0 2010-06-10 0

ORBIMED ADVISORS LLC

ISALY SAMUEL D

  • Director
  • 10% Owner
1,805,100 2009-12-28 0

MULLIGAN WILLIAM C

  • Director
0 2009-06-09 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

WASMAN JANE - Director

2020-11-16 15:44:29 -0500 2020-11-12 A 100,000 a 100,000 direct

KALIN KATHERINE BACH - Director

2020-11-17 16:15:48 -0500 2020-11-12 A 100,000 a 100,000 direct

SHAH BAIJU R. - Director

2020-11-16 15:41:31 -0500 2020-11-12 A 100,000 a 100,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments